ATP synthase membrane subunit c locus 1Genealiases: ATP5A · ATP5G · ATP5G1
Q-omics provides the consensus-scored ATP5MC1 profile across patient tissues and cancer cell-line models. ATP5MC1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ATP5MC1 is differentially expressed in 13, with the highest sampling consensus in LIHC. Additionally, ATP5MC1 RNA expression shows 17,980 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, LIHC, and THYM as cancer lineages where ATP5MC1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ATP5MC1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ATP5MC1 survival associations across molecular data types. ATP5MC1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ATP5MC1 RNA expression–survival associations across cancer types. High ATP5MC1 expression shows unfavorable associations in KIRC, UVM, ACC and SKCM, but favorable associations in SCLC and KIRP. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ATP5MC1 RNA expression.
This table summarizes ATP5MC1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for ATP5MC1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ATP5MC1 shows lower tumor expression in KICH, KIRC and THCA and higher tumor expression in LIHC, LUSC and BRCA. The LIHC box plot shows higher ATP5MC1 RNA expression in tumor versus normal tissue (log2 FC = +1.124, t-test p < 0.001).
This table shows molecular features associated with ATP5MC1 in patient tissues and cancer cell lines. In patient samples, ATP5MC1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ATP5MC1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Myeloma, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BONE.
